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WS), Lübeck, Germany; Institut für Laboratoriumsmedizin und Pathobio-
chemie (WAN), Molekulare Diagnostik, Universitätsklinikum Marburg,
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Abstract: Uromodulin, released from tubular cells of the ascending
limb into the blood, may be associated with kidney function. This work
studies the relevance of plasma uromodulin as a biomarker for kidney
function in an observational cohort of chronic kidney disease (CKD)
patients and subjects without CKD (CKD stage 0). It should be further
evaluated if uromodulin allows the identification of early CKD stages.
Plasma uromodulin, serum creatinine, cystatin C, blood-urea-nitrogen
(BUN) concentrations, and estimated glomerular filtration rate (eGFR
CKD-EPIcrea-cystatin) were assessed in 426 individuals of whom 71 were
CKD stage 0 and 355 had CKD. Besides descriptive statistics, univariate
correlations between uromodulin and biomarkers/eGFR were calculated
using Pearson-correlation coefficient. Multiple linear regression modeling
was applied to establish the association between uromodulin and eGFR
adjusted for demographic parameters and pharmacologic treatment.
Receiver-operating-characteristic (ROC) analysis adjusted for demo-
graphic parameters was performed to test if uromodulin allows differen-
tiation of subjects with CKD stage 0 and CKD stage I.
Mean uromodulin plasma levels were 85.7 60.5 ng/mL for all CKD
stages combined. Uromodulin was correlated with all biomarkers/eGFR
in univariate analysis (eGFR: r¼ 0.80, creatinine: r¼0.76, BUN:
r¼0.72, and cystatin C: r¼0.79). Multiple linear regression mod-
eling showed significant association between uromodulin and eGFR
(coefficient estimate b¼ 0.696, 95% confidence interval [CI] 0.603–usanne Angermann asenau,
Renders, and Jürgen Scherberich
0.831, 95% CI 0.746–0.915, P¼ 0.008) compared to creatinine, cystatin
C, BUN, and eGFR (AUC for creatinine: 0.722, P¼ 0.056, cystatin C:
0.668, P¼ 0.418, BUN: 0.653, P¼ 0.811, and eGFR: 0.634, P¼ 0.823).
Plasma uromodulin serves as a robust biomarker for kidney function
and uniquely allows the identification of early stages of CKD. As a
marker of tubular secretion it might represent remaining nephron mass
and therefore intrinsic ‘‘kidney function’’ rather than just glomerular
filtration, the latter only being of limited value to represent kidney
function as a whole. It therefore gives substantial information on the
renal situation in addition to glomerular filtration and potentially solves
the problem of creatinine-blind range of CKD, in which kidney impair-
ment often remains undetected.
(Medicine 95(10):e3011)
Abbreviations: AUC = area under the curve, BMI = body mass
index, BUN = blood-urea-nitrogen, CKD = chronic kidney disease,
eGFR = estimated glomerular filtration rate, ROC = receiver-
operating-characteristic, UD = underlying disease.
INTRODUCTION
U romodulin is a 95 kDa protein, also known as Tamm-Horsfall protein encoded by the UMOD gene located on
chromosome 16p12.3.1–3 It represents the most abundant urin-
ary protein exclusively produced in the tubular cells of the thick
ascending limb and the early distal tubule.2 Most of the protein
is released into the tubular lumen, forming a layer on the tubular
cell surface.4,5 Its physiological role is hypothesized to protect
tubular cells from ascending urinary tract infection6 and to be
involved in chronic pyelonephritis7 and urolithiasis.8 Addition-
ally to tubular secretion, uromodulin is also released on the
basolateral side of the tubular cell into the interstitium,9 the
physiological reason remains unclear up to now.10 A reduced
number of tubular cells, due to for example, interstitial fibrosis/
tubular atrophy in chronic kidney disease (CKD), is paralleled by
reduced urinary and serum concentrations of uromodulin.11
Therefore, uromodulin might represent a promising biomarker
for the number of intact nephrons and therefore renal mass rather
than only reflecting ‘‘kidney function’’ by measuring glomerular
filtration. In anephric patients, no uromodulin could be detected
in the blood. Urinary uromodulin concentrations have been
studied in the context of CKD and did show some correlation
to kidney/graft function.12–14 Variants of the encoding UMOD
gene were related to rare CKDs, but also urinary uromodulin
levels were influenced by certain variants.15,16 Since more than
5 decades uromodulin is analyzed in urine samples, for example,
applying quantitative radial immunodiffusion technique. How-
ever, due to severe preanalytic limitations and instability of theon (monomer vs multimers) the diagnos-
ses is still questionable and unsuitable in
ligo-/anuria. The significance of serum/
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plasma uromodulin levels in the context of CKD has not been
extensively studied so far. Several small studies delivered prom-
ising but inconsistent results indicating that serum uromodulin
might reflect kidney function in CKD patients but not necessarily
in healthy subjects.11,17,18 The largest study recently published
involved only elderly healthy patients.19
In this study, we evaluated plasma uromodulin as a bio-
marker of kidney function in patients with different stages of
CKD and individuals without CKD. We additionally questioned
whether plasma uromodulin is able to identify early stages of




The cohort consisted of 426 patients with 71 patients
without kidney disease (CKD 08) serving as a control group
and 355 patients of stages I8–V8of CKD. The study was based
on a prospective, observational study concept. The study was
approved by the local ethics committee of Klinikum rechts der
Isar, Technische Universität, Munich, Germany and adheres to
the declaration of Helsinki. All patients enrolled in this study
gave their informed consent.
Patient’s Demographic Data, Inclusion Criteria,
Definition of CKD, and Laboratory Parameters
We included 355 patients presenting to our nephrological
outpatient clinic at Klinikum rechts der Isar, Munich, Germany.
Inclusion criteria followed the definitions for CKD according to
the last KDIGO guidelines20: ‘‘CKD is defined as abnormalities
of kidney structure or function, present for >3 months, with
implications for health.’’ Therefore, the diagnosis of CKD was
made when either estimated glomerular filtration rate (eGFR)
was <60 mL/min and/or apparent signs of kidney damage were
present. As apparent signs of kidney damage we considered
proteinuria with a cut-off >150 mg/g creatinine on spot urine
specimen and/or histologically proven kidney disease and/or
abnormalities detected in imaging techniques (ultrasound, com-
puted tomography, magnetic resonance imaging, or nuclear
imaging). Calculation of eGFR was based on both serum
creatinine and cystatin C concentration (CKD-EPIcrea-cystatin).
21
Once the diagnosis of CKD was established, patients were
assigned to a certain stage of CKD according to the KDIGO
recommendation: CKD I8 when eGFR >90 mL/min, CKD II8
61 to 90 mL/min, CKD 38 31 to 60 mL/min, CKD IV8 16 to
30 mL/min, and CKD V8 0 to 15 mL/min. Patients with a single
kidney (e.g., due to nephrectomy) were assumed to have CKD
despite an eGFR >60 mL/min. Furthermore, we included 71
individuals without medical history for CKD and an eGFR
>60 mL/min (CKD 08). Besides uromodulin, creatinine, blood-
urea-nitrogen (BUN), and cystatin C were measured in the
plasma samples and eGFR (CKD-EPI
crea-cystatin
) was calculated.
Protein-to-creatinine ratio of spot urine sample was measured.
The following patient data were assessed: age, gender, body
mass index (BMI), systolic/diastolic blood pressure, history of
diabetes mellitus, arterial hypertension and underlying disease
(UD), serum c-reactive protein, sodium, potassium, total
protein, uric acid, glutamic-pyruvic-transaminase, and com-
plete blood count.
Steubl et alPrimary analysis was the correlation of plasma uromodulin
with eGFR (CKD-EPIcrea-cystatin) in the whole cohort and
advanced stages of CKD separately. Secondary analyses were
2 | www.md-journal.comcorrelation of plasma uromodulin with serum creatinine, cysta-
tin C, BUN, and proteinuria. Additionally, we evaluated the
difference of plasma uromodulin, serum creatinine, BUN, and
cystatin C concentrations as well as eGFR between patients at
CKD I8/II8 and CKD 08. Furthermore, we analyzed if plasma
uromodulin differs significantly between CKD 08 and all stages
of CKD and CKD III8–V8, respectively. Patients’ demographics
are given in Table 1.
Biomarker Measurements and eGFR Equations
All plasma samples were stored at – 80 8C before measure-
ments were performed. Plasma uromodulin measurements were
performed using a commercially available assay (Euroimmun
AG, Lübeck, Germany). Short performance characteristics of
the ELISA for plasma samples given by the manufacturer:
detection limit for plasma samples 2 ng/mL; mean linearity
recovery 97% (83%–107% at 59–397 ng/mL); intraassay pre-
cision 1.8–3.2% (at 30–214 ng/mL), interassay precision 6.6%
to 7.8% (at 35–228 ng/mL), and interlot precision 7.2% to
10.1% (at 37–227 ng/mL). Plasma samples were diluted
1:101 using dilution buffer. A total of 100 mL of calibrators,
controls, or diluted samples were pipetted into coated wells of
the microtiter plate (MTP), subsequently 100 mL of biotinylated
detection antibody (final concentration 50 ng/mL) were added.
The MTP was covered with foil and incubated for 2 hours at 450
rotations per minute (rpm) and room temperature on a rotary
shaker. After 2 hours the MTP was washed 3 times using 300 mL
washing buffer, then the wells were tapped gently. A total of
100 mL of steptavidin-polyperoxidase (SPO, final concentration
67 ng/mL) were pipetted into each well followed by another
incubation for 30 minutes at 450 rpm. Subsequently, the SPO
was soaked and the MTP washed 3 times with 300 mL of
washing buffer. Consequently, 100 mL of substrate solution
(containing the chromogen tetramethylbenzidin and hydrogen
peroxide as the substrate for SPO) were pipetted into each well.
The MTP was incubated in the dark for 15 minutes at room
temperature. The reaction was terminated by adding 100 mL of
stop solution. This causes a color change from blue to yellow.
Finally, the substrate solution was measured using a photometer
at a wavelength of 450 nm and reference wavelength of 620 nm.
Data analysis was performed using the program Magellan
(Tecan). Creatinine and BUN were measured by photometric
techniques (creatinine: normal range 0.7–1.3 mg/dL in males
and 0.5–1.1 mg/dL in females; BUN: normal range 7–18 mg/
dL). Cystatin C levels were assessed using a nephelometric
immunoassay (normal range 0.50–0.96 mg/L). The eGFR
equation was calculated based on serum creatinine and cystatin
C concentrations as published.21
Statistics
For statistical analysis IBM SPSS 20 and R 3.1.022 were
used. Continuous data are expressed as mean with standard
deviation. Categorical variables are reported in absolute num-
bers and percentages. Differences between mean uromodulin
values in adjacent CKD stages were analyzed using student’s t-
test. For calculation of univariate correlations between demo-
graphic variables and biomarker concentrations Pearson corre-
lation coefficient was applied with parameters transformed into
logarithmic scales. Pearson correlation coefficient was also
used to calculate univariate correlations between plasma uro-
Medicine  Volume 95, Number 10, March 2016modulin and creatinine, cystatin C, BUN, eGFR (CKD-EPIcrea-
cystatin), and proteinuria, all parameters were transformed into
logarithmic scales. In order to adjust for age, gender, BMI, UD,
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and prescription of various medications that might affect tubular
function (ACE-inhibitors [ACEI]/AT1-receptor blockers
[ARB], calcineurininhibitors, aldosterone antagonists, statins,
nonsteroidal-antiinflammatory drugs [NSAID], acetylsalicylic
acid [ASA], thiazide and loop diuretics, and uric acid lowering
agents, Table 1) multiple linear regression modeling using was
performed to assess the association between uromodulin (inde-
pendent variable) and eGFR (CKD-EPIcrea-cystatin)/proteinuria
(dependent variable). For this purpose, uromodulin, eGFR, and
proteinuria were transformed into logarithmic scales. To evalu-
ate if the association of uromodulin and eGFR varies in different
stages of CKD, both univariate correlation and multivariate
linear regression analysis (the latter adjusted for the same
parameters as in the previously described analysis) was per-
formed between (log) uromodulin (independent variable) and
eGFR (dependent variable) in patients at CKD stage IV8–V8.
Finally, the diagnostic characteristics of all parameters to
distinguish patients with CKD 08 and stage I8 and II8 CKD
as well as CKD 08 versus all CKD stages and stage III8–V8,
respectively, were evaluated using univariate Wilcoxon rank test
and/or receiver-operating-characteristic (ROC) analysis. To
take into account the effect of age, gender, and BMI, a logistic
regression model was fitted to ‘‘stage’’ with these covariates in
an ROC analysis performed based on this model using pROC.23
Then the biomarkers/eGFR was added one by one to this model
assessing whether the addition of variables improved the diag-
nostic ability in terms of ROC curve and increase of area under
the curve (AUC).24 The optimal cut-off to distinguish CKD
stages from each other was calculated using univariate ROC
analysis, since the multivariate analysis is based on a linear
combination of variables from a logistic regression model so its
optimal cut-off value is not meaningful.
All reported P-values are 2-sided, with a significance level
of 0.05, and have not been adjusted for multiple testing. The




The mean age of all subjects was 56.8 16.4 years, 248
Steubl et al(58.2%) were male. Glomerulonephritis of different causes was
the most frequent UD (26.5%), 20.7% had an accompanying
diabetic disease, 65.7% suffered from arterial hypertension.









08 (n¼ 71) 167.6 53.6t 0.65 0.17v 0.86
I8 (n¼ 38) 111.0 42.6t, u 0.58 0.18v 0.98
II8 (n¼ 68) 107.3 49.5t, u 0.91 0.16 1.26
III8 (n¼ 127) 71.0 38.7t 1.44 0.29 1.68
IIIa8 (n¼ 53) 83.9 37.7t 1.22 0.14 1.45
IIIb8 (n¼ 74) 61.7 37.0t 1.59 0.27 1.84
IV8 (n¼ 81) 38.1 19.1t 2.41 0.50 2.84
V8 (n¼ 41) 24.8 13.4t 3.52 0.63 6.00
Data are presented as mean standard deviation or as absolute numbers (n
P¼ 0.382; mean concentrations at stages with the same letter differ at
CKD¼ chronic kidney disease, CKD-EPI¼Chronic Kidney Disease Epide
4 | www.md-journal.comPostrenal failure (n¼ 29) was due to chronic postrenal obstruc-
tion (e.g., retroperitoneal fibrosis), chronic pyelonephritis, or
hereditary abnormalities of the urogenital tract but not acute
postrenal obstruction. Thus, patients had stable eGFR over at
least the last 3 months. Detailed baseline characteristics of the
participants are presented in Table 1.
Uromodulin Concentrations at Different Stages
of CKD
Uromodulin concentrations gradually decreased with pro-
gressive impairment of kidney function, ranging from 281 in
CKD II8 to 3 ng/mL in CKD V8. The mean level in CKD I8 was
111.0 ng/mL, 107.3 ng/mL in CKD II8, 71.0 ng/mL in CKD III8,
38.1 ng/mL in CKD IV8, and 24.8 in CKD V8. The highest value
was detected in a patient with CKD 08 (312 ng/mL). The
difference between uromodulin plasma concentrations for all
pairs of CKD stages (P< 0.001) was significant except for
stages I8 and II8 (P¼ 0.936, Table 2).
Correlation of Uromodulin With Conventional
Biomarkers, eGFR, and Proteinuria
In univariate analysis, plasma uromodulin concentrations
were significantly associated with all biomarkers and eGFR
calculations, being highest for eGFR (CKD-EPIcrea-cystatin,
r¼ 0.80, P< 0.001) followed by cystatin C (r¼0.79,
P< 0.001), creatinine (r¼0.76, P< 0.001), and BUN
(r¼0.72, P< 0.001, Figure 1). The correlation between
uromodulin and proteinuria was weaker, however still signifi-
cant (r¼0.273, P< 0.001). As uromodulin had inverse
kinetics compared to conventional biomarkers of decreasing
concentrations with progressive impairment of kidney function
the correlations with eGFR calculations were positive, whereas
inverse correlations were found with other biomarkers. In
multiple linear regression modeling adjusting for age, gender,
BMI, UD, and pharmacological treatment (all dependent vari-
ables) the coefficient estimate between uromodulin (log, inde-
pendent variable) and eGFR (CKD-EPIcrea-cystatin, log, and
dependent variable) was 0.696 (95% confidence interval [CI]
0.603–0.719, P< 0.001, Figure 2), resulting in R2¼ 0.837.
Thus, 83.7% variation of eGFR (log) can be explained by
Medicine  Volume 95, Number 10, March 2016the parameters included in the study. The coefficient estimate
between uromodulin (log, independent variable) and proteinuria








 0.21w 13.5 3.8x 108.4 21.6y
 0.30w 14.8 4.8x 112.5 20.5y
 0.27 19.4 5.2 73.1 8.7
 0.42 27.3 9.2 43.6 8.3
 0.29 23.6 6.7 51.9 4.5
 0.43 30.1 9.8 37.6 4.4
 0.83 43.1 12.7 22.5 4.6
 2.60 63.9 16.8 11.5 3.0
). t: P< 0.001, u: P¼ 0.936, v: P¼ 0.038, w: P¼ 0.074, x: P¼ 0.278, y:
a P-level of significance as indicated. BUN¼ blood-urea-nitrogen,
miology Collaboration, eGFR¼ estimated glomerular filtration rate.




Medicine  Volume 95, Number 10, March 2016 Plasma Uromodulin in Chronic Kidney Diseasethe calculation between uromodulin and eGFR was 0.393
(95% CI (0.922)–(0.555), P< 0.001, Figure 2), resulting in
R2¼ 0.523. We further tested if plasma uromodulin correlates
with eGFR in advanced stages of CKD (IV8 and V8) using
univariate correlation and multivariate regression analysis,
since in these stages the variation of conventional biomarkers
such as creatinine shows a wider range. In both univariate
correlation and multivariate regression analysis, the corre-
lation/the regression estimate remained significant (univariate
correlation r¼ 0.487, P< 0.001; multivariate regression coef-
ficient estimate b¼ 0.420, 95% CI 0.170–0.421, P< 0.001).
Since diabetes was underrepresented in our cohort in
comparison to the general population we analyzed the associ-
FIGURE 1. Relationship between plasma uromodulin and (A) seru
eGFR (CKD-EPIcrea-cystatin). r¼ correlation coefficient of univariate
Disease Epidemiology Collaboration, eGFR¼ estimated glomerulaation between plasma (log) uromodulin and (log) eGFR only in
this subcohort (n¼ 28) using univariate Pearson correlation
coefficient and multivariate linear regression analysis.
FIGURE 2. Relationship between logarithmic plasma uromodulin and
ular filtration rate. CKD¼ chronic kidney disease, CKD-EPI¼Chronic
glomerular filtration rate.
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.Univariate correlation was 0.716 (P< 0.001), in multivariate
regression analysis the coefficient estimate was 0.666 (95%CI
0.273–0.976, P¼ 0.002). Both analyses of the subcohort deliv-
ered comparable results, which were found during calculations
performed using data from whole cohort.
Comparison of Patients Without CKD and CKD
I-/CKD II-/CKD I-–V- and III-–V-
When comparing early stages of CKD and subjects without
CKD, uromodulin concentrations differed significantly
between both CKD 08 and I8 (167.6 vs 111.0 ng/mL,
P< 0.001, Table 2) and CKD 08 and CKD II8 (167.6 vs
107.3 ng/mL, P< 0.001, Table 2). None of the other parameters
reatinine, (B) serum cystatin C, (C) blood urea nitrogen, and (D)
alysis. CKD¼ chronic kidney disease, CKD-EPI¼Chronic Kidney
tration rate.differed significantly between CKD 08 and I8 in univariate
analysis (creatinine: P¼ 0.074; BUN: P¼ 0.278; eGFR [CKD-
EPIcrea-cystatin]: P¼ 0.382, Table 2). Cystatin C levels were
logarithmic eGFR (CKD-EPIcrea-cystatin). eGFR¼ estimated glomer-
Kidney Disease Epidemiology Collaboration, eGFR¼ estimated
www.md-journal.com | 5
patients with CKD III8–V8 further increased the AUC to
FIGURE 3. Multivariate ROC analysis evaluating the ability of
different parameters to distinguish patients without CKD and
CKD stage I8; all parameters (uromodulin, creatinine, cystatin
C, BUN, and eGFR) adjusted for age, gender, and BMI; purple
line indicates the ability of age, gender, and BMI alone to differ-
entiate between both groups. BMI¼body mass index, BUN¼
Steubl et alhigher in the CKD 08 group compared to CKD I8 (P¼ 0.038,
Table 2). All parameters were significantly different between
CKD 08 and II8 (P< 0.001 resp.). However for creatinine,
cystatin C, and eGFR this finding was obvious since the
classification of CKD was based on eGFR calculated from
creatinine and cystatin C.
In the ROC analysis, age, gender, and BMI alone resulted
in an AUC of 0.632 to discriminate between CKD 08 and I8
(representing adjustment for these parameters). Adding uromo-
dulin to the model resulted in a significant increase of the AUC
to 0.831 (95% CI 0.746–0.915, P¼ 0.008, Figure 3) at an
optimal cut-off of 142.3 ng/mL with 64.8% sensitivity and
83.8% specificity (the latter data from univariable ROC
analysis). None of the other biomarkers/eGFR contributed to
the model regarding increase of the AUC (creatinine: AUC
0.722, 95% CI 0.612–0.831, P¼ 0.056, cystatin C: AUC 0.668,
95% CI 0.556–0.781, P¼ 0.418, BUN: AUC 0.653, 95% CI
0.529–0.776, P¼ 0.811, eGFR: AUC 0.634, 95% CI 0.517–
0.751, P¼ 0.823, Figure 3), meaning that none of the bio-
markers added to age, gender, and BMI significantly helped to
discriminate between CKD 08 and I8. Combining eGFR and
uromodulin in an ROC analysis adjusted for age, gender, and
BMI did not improve the AUC compared to the model of age,
gender, BMI, and uromodulin alone (AUC 0.829, 95% CI
0.744–0.914, P¼ 0.009).
In order to assess the ability of plasma uromodulin to
differentiate between non-CKD subjects and patients of all
CKD stages we performed multivariable ROC analysis. Uro-
blood-urea-nitrogen, CKD¼ chronic kidney disease, eGFR¼
estimated glomerular filtration rate, ROC¼ receiver-operating-
characteristic.modulin, in addition to gender, BMI, and age resulted in an
increased AUC of 0.924 (95% CI 0.892–0.956, P< 0.001)
compared to the AUC for gender, BMI, and age alone (AUC
6 | www.md-journal.com0.743, 95% CI 0.677–0.808). Limiting the CKD group to
Medicine  Volume 95, Number 10, March 20160.971 (95% CI 0.951–0.992, P< 0.001) from 0.817 (95% CI
0.756–0.878).
DISCUSSION
This is to our knowledge the largest study assessing the
performance of plasma uromodulin, a marker representing
tubular function and therefore differing substantially from all
conventional glomerular filtration biomarkers, concentration as
marker for kidney function in both CKD patients as well as
patients without CKD. Plasma uromodulin seems to be working
as a marker for kidney function in both CKD patients as well as
patients without CKD. Unlike other conventional biomarkers
for kidney function, uromodulin concentrations were signifi-
cantly higher in individuals without CKD compared to patients
at all stages of CKD, especially in patients at early stages of
kidney disease (CKD I8), presumably due to the fact that no
evasion mechanism for tubular function exists in contrary to
glomerular filtration. Uromodulin allowed to distinguish
between patients without CKD and patients at all stages of
CKD by simply assessing plasma concentrations, at a reason-
able level of sensitivity and specificity outperforming all other
biomarkers tested in this study.
In our study, plasma uromodulin confirmed the previously
documented19 inverse behavior compared to other biomarkers
resulting in lower plasma uromodulin concentrations at
advanced stages of CKD. From the current pathophysiological
understanding this circumstance is due to the fact that uromo-
dulin may not be, like creatinine and BUN, an indirect marker
for glomerular filtration but a direct marker for the amount of
intact tubular cells of the ascending limb (where it is exclusively
produced) and therefore may represent a marker for the number
of remaining functional nephrons/renal tissue/tubular secretion.
This is a novel approach to measure ‘‘kidney function,’’
potentially helping the treating physician to assess the remain-
ing renal mass and therefore kidney function in the phase when
conventional markers/glomerular filtration fails to indicate
deterioration of kidney function.
The scatterplot in Figure 1 illustrates another important
finding: unlike conventional glomerular filtration markers
(creatinine, BUN, and cystatin C), which show hyperbolic
correlation to eGFR, uromodulin exhibits linear correlation
to eGFR. Therefore, there is no need to take into account the
stage of CKD, when for example, for creatinine changes
between 1 and 2 mg/dL represent pronounced changes of kidney
function, whereas changes between 5 and 6 mg/dL do not.
Therefore, it appears that changes of uromodulin concentrations
are much easier to be interpreted.
Concerning confounding factors influencing plasma uro-
modulin concentrations, we detected that age and BMI were
weakly, but statistically significantly inversely correlated with
serum uromodulin (lower uromodulin levels correlate with
higher age and BMI). Risch et al19 also detected in their study
that age was inversely correlated to uromodulin
serum concentrations.
The fact that plasma uromodulin concentrations differ
between subjects without CKD, and early stages of CKD might
bridge the gap of current biomarkers for kidney function. Due to
the curvilinear relationship between serum creatinine and eGFR
based on the mathematical relationship GFR serum
creatinine¼ 24 hour urine creatinine excretion (equation apply-
ing to a steady state), creatinine serum concentrations tend to
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.
rise in serum only when approximately 40% to 50% of renal
parenchyma is reversibly or irreversibly damaged. Therefore,
early stages of acute or chronic kidney failure are often over-
looked, a circumstance that delays possible diagnostic and
therapeutic interventions, for example, kidney biopsy followed
by immunosuppressive treatment in autoimmune or inflamma-
tory diseases. Our data suggest that impaired kidney function of
any reason impairs tubular function of the ascending limb
already in early phases of the disease. This leads to decreased
uromodulin plasma concentrations. Whether this also holds true
for situations of acute kidney failure needs to be evaluated in
the future.
Our data are in contrast to data from Prajczer et al.11
Applying their own assay, these authors describe a weak but
positive correlation between a decrease in GFR and a rise of
serum uromodulin, where statistical significance was not
achieved. Similar to our study, mainly patients with glomer-
ulonephritis were included, thus, the reason for these discrepant
findings remains unknown. However, Thornley et al17 also
detected the correlation of serum uromodulin and GFR,
measured by creatinine clearance. However, they failed to show
a correlation in healthy subjects. We assume that the results
obtained in this study that dates back to 1980 are not unrest-
rictedly comparable to our results, since diagnostic accuracy of
uromodulin measurements might have changed over 30 years of
research. Dawnay and Cattell18 and Risch et al19 achieved
similar results to our study showing that serum uromodulin
is related to kidney function. However, they did not perform
analyses comparing subjects without CKD with patients at
various stages of CKD. Risch et al included patients who felt
subjectively healthy but did not undergo proper nephrologic
evaluation in the form of quantification of proteinuria or sono-
graphic evaluation, so the actual nephrological situation in these
patients remained unclear. Another limitation of the study is that
only diabetic patients aged over 60 years were included. Also a
cruder classification of CKD was performed in the study, with
patients at an eGFR below 45 mL/min being classified as 1
group. Therefore, we think our results are more generalizable
and add substantial impact to the topic. Future studies need to
further validate our results of plasma uromodulin being a
marker for the detection of early stages of CKD. Other bio-
marker studies identifying early stages of CKD are not avail-
able. Cystatin C was beneficial to identify early stages of
diabetic nephropathy25 but not in the general CKD population.
Since proteinuria is known to be a strong predictor of CKD
progression26 we evaluated the association of plasma uromo-
dulin with proteinuria and detected a significant association in
multivariate analysis. This raises the hypothesis whether uro-
modulin might also serve as a predictor for CKD progression.
This might be evaluated in future studies.
Since research up to now focused mainly on urinary
uromodulin as a marker of CKD with a recent publication also
documenting the predictive value of urinary uromodulin in
CKD,27 we compared the diagnostic accuracy of plasma versus
urinary uromodulin. For this purpose we compared plasma and
urine samples of 335 patients of the cohort. In univariate
analysis using Pearson correlation coefficient urinary uromo-
dulin correlated eGFR (r¼ 0.581, P< 0.001) to a lesser extent
than plasma uromodulin (r¼ 0.786, P< 0.001). When we
applied the similar multivariable linear regression analysis as
in the main study using logarithmic data with eGFR being the
Medicine  Volume 95, Number 10, March 2016dependent variable and uromodulin being the independent one
adjusted for age, BMI, gender, UD, and pharmacologic treat-
ment results were similar (urinary uromodulin: b¼ 0.509, 95%
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.CI 0.278–0.688, P< 0.001; plasma uromodulin: b¼ 0.699,
95% CI 0.601–0.733, P< 0.001). At last, in univariable
ROC analysis performed to assess the ability of the biomarkers
to discriminate between non-CKD and CKD I8 patients, the
AUC value of plasma uromodulin (AUC¼ 0.847, 95% CI
0.750–0.945, P< 0.001) was again higher than the AUC value
of urinary uromodulin, which was not able to differentiate
between CKD 08 and CKD I8 (AUC¼ 0.546, 95% CI
0.393–0.699, P¼ 0.542). Comparing CKD 08 and the group
of patients with CKD III8–V8 pooled in ROC analysis, plasma
uromodulin delivered a better AUC value (0.971, 95% CI
0.946–0.995, P< 0.001) compared to urinary uromodulin
(0.784, 95% CI 0.712–0.857, P< 0.001) to discriminate these
groups. Taken the results of these analyses together, plasma
uromodulin appears to outperform urinary uromodulin in terms
of correlation/association with eGFR, identification of early
stages of CKD, and discrimination of non-CKD versus
advanced CKD stages.
Our study has certain limitations. At first we used eGFR
but did not compare plasma uromodulin to a reference method
of kidney function such as inulin clearance due to feasibility
reasons. However, we used the most accurate eGFR currently
available, incorporating both creatinine and cystatin C.21
Furthermore, since we evaluated a marker for tubular function
it was not necessary to use the gold standard for glomerular
filtration but only evaluate correlation to glomerular filtration in
general. The diagnosis of proteinuria was established using
protein/creatinine ratio in a spot urine sample. As estimation of
proteinuria/creatinine ratio from spot urine was documented to
be less reliable than proteinuria/creatinine ratio from a 24 hour-
urine collection in lupus nephritis patients, it might have been
more accurate to establish the diagnosis of proteinuria based on
protein/creatinine ratio from a 24 hour-urine collection.28 We
also included mainly Caucasian subjects, a circumstance that
limits the transfer of the results to other subjects with a different
ethnic background. Concerning UD chronic glomerulonephritis
was predominant. Since diabetic nephropathy is the main cause
of CKD in the general CKD population, the results of the study
might not be simply transferred to the general population. To
account for this we analyzed the association of plasma uromo-
dulin and eGFR using univariate correlation and multivariate
regression analysis exclusively in the subcohort with diabetic
nephropathy. In both analyses, the association was similar as in
the total cohort, so we consider that the specific composition of
our cohort does not hamper the results significantly. However,
especially the value of uromodulin to detect early stages of
CKD needs to be validated in other cohorts with a higher
proportion of patients with diabetic nephropathy. Demographic
data especially between CKD 08 and I8 were different; there-
fore, we used adjusted multivariate regression modeling and
adjusted ROC analysis to eliminate possible demographic
confounders. We did not perform an analysis of the uromodulin
gene in the patients of our cohort. Mutations in the uromodulin
gene may end in a misfolding of the uromodulin molecule,
which in turn leads to decreased secretion and accumulation in
the tubular cell29–31 and possibly reduced uromodulin plasma
concentrations. However, since diseases based on mutations in
the uromodulin genes are reported to be very rare (reported
prevalence of 1.7 cases in 1,000,000) we do not think that this
possible confounder affected our results substantially.32 In
addition, since the aim of the study was to evaluate uromodulin
Plasma Uromodulin in Chronic Kidney Diseaseas a universal biomarker of kidney function/remaining func-
tional renal parenchyma it would have been a methodological
problem to specifically address this issue. Although the total
www.md-journal.com | 7
number of patients was adequate to run a meaningful statistical
analysis, the number of patients in the particular CKD groups
(except CKD III8) was below 100. Nevertheless significant
preliminary results could be achieved, so this study laid the
basis for future studies addressing specific subgroup analyses
with bigger cohorts. At last, our study was performed cross-
sectional; therefore, we cannot make a statement on the prog-
nostic value of plasma uromodulin levels and on the develop-
ment of plasma uromodulin concentrations in the course of
changes of kidney function in single patients.
In conclusion, we consider plasma uromodulin a prom-
ising biomarker for the assessment of ‘‘kidney function,’’
defined as the remaining number of functional tubular cells
in patients with and without CKD. It uniquely allows the
identification of early stages of CKD when conventional
biomarkers of kidney function, which are all markers of
glomerular filtration, are still within normal range. Due to
its site of production in tubular cells of the ascending limb,
uromodulin might represent a marker quantifying the amount
of intact renal parenchyma as useful tool amending established
biomarkers only reflecting glomerular filtration. Based on our
findings, future evaluation of ‘‘kidney function’’ might consist
of a combination of measurement of glomerular filtration AND
tubular secretion capacities. Whether uromodulin is important
in other clinical settings, such as acute kidney failure needs to
be addressed in future studies.
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